Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals’ Lasofoxifene Demonstrates Anti-Estrogen Therapy Increases Immunotherapy Efficacy by Promoting Antitumor Activity of Eosinophils

The findings were published Sept. 27 in the peer-reviewed journal Science AdvancesLasofoxifene was more effective than fulvestrant in inhibiting estrogen activity in mice models COLUMBUS, Ohio,...
December 17, 2020 08:00 ET | Source: Biotheranostics, Inc.

Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients

San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage...
December 08, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020

San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held...
December 03, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology

San Diego, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology in support of Breast Cancer Index, the only commercially...
May 15, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial

San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...
February 24, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology

San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
December 11, 2019 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test

San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for...